Women travel thousands of miles for a reproductive moonshot at an Albanian clinic
A Dutch patient underwent a complex IVF procedure in Tirana that combined her own DNA with a Ukrainian egg donor’s material.
Driving from Tirana International Airport toward the city centre, the scenery shifts from modern car dealerships to rows of concrete housing blocks painted in bright colors. Further south, newly paved roads climb toward upscale neighborhoods surrounded by high walls and security gates.
Amid these luxury homes sits a red‑bricked building that houses the SAGA Clinic. A small courtyard and a sign displaying the U.S. Food and Drug Administration logo proclaim it an “FDA registered facility.”
In February, a Dutch woman named Wendy arrived at the clinic. While waiting, she stood beneath a three‑foot‑tall fetal sculpture carved into the slate‑colored lobby wall. She was then escorted to a private exam room.
From the exam chair, Wendy watched a grainy ultrasound of her uterus as a doctor threaded a catheter and gently deposited an embryo. This step was part of an in‑vitro fertilization (IVF) cycle she had undergone several times before.
Unlike her previous cycles, this embryo contained genetic material from three individuals: Wendy, her partner, and a third‑party egg donor from Ukraine.
Key points about the procedure
Location: SAGA Clinic, Tirana, Albania.
Patient: Wendy, a Dutch national seeking fertility treatment.
Technique: IVF with a donor egg, creating a “three‑parent” embryo.
Clinic claim: The facility is “FDA registered,” suggesting U.S. oversight.
Scientific concern: Experts say the clinic’s advertising may mislead patients about regulatory approval and the experimental status of the treatment.
The journey underscores how women travel great distances for reproductive technologies that may not be fully vetted by the regulatory bodies they reference. Scientists caution that the clinic’s portrayal of FDA registration could give a false sense of safety and legitimacy.
As more patients seek such “moonshot” fertility options abroad, the need for clear, accurate information about regulatory status and medical risk becomes increasingly urgent.
